[Translation] A Phase II, randomized, open-label, active-controlled, multicenter study to evaluate the safety and serum phosphorus-lowering effect of AP-306 in patients with chronic kidney disease and hyperphosphatemia receiving maintenance hemodialysis
本研究的主要疗效目的是根据以下终点评价 AP-306 的有效性:在接受维持性血液透析的高磷血症患者中探索 AP-306 降低血清磷水平的能力;安全性目的是评价AP-306的总体安全性和耐受性。
[Translation] The primary efficacy objective of this study is to evaluate the effectiveness of AP-306 based on the following endpoints: exploring the ability of AP-306 to reduce serum phosphorus levels in patients with hyperphosphatemia receiving maintenance hemodialysis; the safety objective is to evaluate the overall safety and tolerability of AP-306.